Pharma Focus Europe

Cancer Research UK and Guardant Health Collaborate to Propel Progress in Cancer Research and Clinical Development Activities

Monday, December 04, 2023

Cancer Research UK, a major global funder of cancer research, and Guardant Health, a leading precision oncology company, have recently announced a collaboration aimed at enhancing the development and precision of cancer detection and treatment. The partnership seeks to facilitate the exchange of technologies, data, and insights, with a specific emphasis on supporting Cancer Research UK's clinical trials, including the groundbreaking DETERMINE trial – the first UK national precision medicine trial focused on rare cancers.

Within this collaboration, there is potential for sharing data and samples from Cancer Research UK-funded research to validate Guardant's technologies and explore various projects aimed at expediting the discovery and development of cancer drugs and diagnostics. Helmy Eltoukhy, co-CEO of Guardant Health, expressed excitement about the collaboration and its potential to support individuals with rare cancers, emphasizing the advancement of precision oncology. Guardant Health aims to combine its cutting-edge biotechnology with Cancer Research UK's extensive reach, which includes involvement in over 200 clinical trials and studies with more than a million participants in the UK.

Tony Hickson, Chief Business Officer for Cancer Research UK and Cancer Research Horizons, highlighted the promising prospects of applying data-driven insights and technologies to detection and treatment studies. The collaboration is expected to have a positive impact on the efforts of the Centre for Drug Development in bringing novel therapeutics to first-in-human trials.

Guardant Health's oncology platform, featuring tests like Guardant360®, Guardant360 CDx, and GuardantOMNI®, focuses on driving commercial adoption, improving patient outcomes, and reducing healthcare costs throughout the cancer care continuum. The collaboration with Cancer Research UK is viewed as a strategic partnership that leverages the strengths of both organizations to advance cancer research and treatment.

 

Source: businesswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva